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Background: A couple of studies indicate a favorable impact of lupin protein on cardiovascular risk factors in
humans. These studies, however, used relatively high doses of > 33 g/d, which can hardly be consumed under
physiological conditions. Therefore, we investigated the effect of 25 g/d lupin protein isolate (LPI) on selected
cardiovascular markers and on serum amino acids.
Methods: A total of 33 hypercholesterolemic subjects participated in a randomized, controlled, double-blind
crossover study. LPI and the active comparator milk protein isolate (MPI) were incorporated in protein drinks and
consumed over 8 wk separated by a 4 wk washout period. Anthropometric data, blood pressure, and nutrient
intake were assessed at baseline and after 8 wk of both protein interventions. Blood was sampled at baseline, wk 4
and wk 8. All 33 subjects were included in final statistical analyses using repeated measures ANOVA with the
general linear model or using linear mixed model.
Results: Except for higher HDL cholesterol at wk 4 of LPI (P ≤ 0.036), anthropometric parameters, blood pressure,
and plasma lipids did not differ among LPI and MPI intervention. Compared to baseline, the primary outcome LDL
cholesterol was significantly reduced after 4 wk of both interventions (P ≤ 0.008), while LDL:HDL cholesterol ratio
was decreased only by LPI (P = 0.003). These time effects were restricted to subjects with higher
hypercholesterolemia and disappeared after 8 wk. Blood pressure was reduced after 8 wk of LPI (P ≤ 0.044). Almost
all serum amino acids were higher at wk 4 but not at wk 8 of MPI compared to LPI. Following 4 wk and 8 wk of LPI
intervention, most amino acids remained unchanged. Both interventions caused a slight, but significant rise in body
weight and body fat after 8 wk (P ≤ 0.045).
Conclusion: In conclusion, 25 g LPI can beneficially modulate plasma LDL cholesterol at least over short-term.
Using appropriate dietetic conditions that improve consumer compliance and avoid changes in energy intake as
well as in body composition, lupin protein could positively impact cardiovascular risk factors particularly in
individuals with higher hypercholesterolemia.
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Replacing of animal by plant protein in foods is currently
an important topic of discussion due to the ecological and
physiological benefits associated with vegetable sources of
proteins. In view of the growing global population as well
as the limited availability of agricultural land, there is an
urgent need for high quality proteins from sustainable
plant sources such as legumes (e.g., soy, pea, and lupin).
Moreover, the rising incidence of cardiovascular diseases
increases the demand for potential dietary interventions
that could reduce the related risk factors. For established
cardiovascular conditions such as coronary heart diseases
and also for subjects at high risk, drug therapy is the
recommended form for reducing elevated LDL cholesterol
concentrations [1]. However, ancillary to an existing ther-
apy or for the primary prevention of coronary heart dis-
eases, non-pharmacological strategies such as weight
reduction, increased physical activity, and healthier dietary
habits are endorsed by the National Cholesterol Education
Program (NCEP) [1].
Dietary proteins from plant sources can exert nutraceut-
ical activities such as reduce blood lipids and lower blood
pressure [2-5], and thus constitute a healthier diet. As
reviewed by Sirtori et al. [2], investigations in animals have
revealed that proteins derived from either white lupin
(Lupinus albus) or blue lupin (Lupinus angustifolius) im-
prove the lipoprotein profile and lower blood pressure.
Most of the studies in humans evaluated the physiological
effects of lupin flour or lupin fiber, and only a small num-
ber of investigations focused on the effects of lupin protein
[6]. These studies observed a beneficial influence of lupin
protein on blood cholesterol concentrations [7-9] and also
partially on blood pressure [7]. Furthermore, the study by
Naruszewicz et al. [7] revealed a significant reduction of
the inflammatory marker “high-sensitivity C-reactive pro-
tein” (hs-CRP) after 90 d of lupin protein intake in hyper-
cholesterolemic subjects. As shown in a prospective study
in women, hs-CRP is a strong predictor of the risk of car-
diovascular events [10]. The effect of lupin protein on the
distribution of serum amino acids has only been examined
in one human trial [8]. Most importantly, in all of these
studies, relatively high doses comprising more than 30 g/d
lupin protein were administered [7-9]. Such high daily
doses can hardly be consumed under normal physiological
conditions. For example, for soy protein, which is closely
related to lupin protein, the US Food and Drug Adminis-
tration established a health claim in 1999 stating that the
intake of 25 g/d soy protein beneficially affects serum
lipids in humans [11]. Thus, further studies are needed to
firstly, evaluate the impact of an equivalent modest
amount of lupin protein on cardiovascular health and sec-
ondly, to clarify the effect on serum amino acids.
Therefore, we conducted a randomized crossover
intervention study to determine the impact of 25 g/dsupplemental lupin protein isolate (LPI) compared to
milk protein isolate (MPI) incorporated into protein
drinks on cardiovascular markers (blood lipids, hs-CRP,
and blood pressure) and on the amino acid profile in
hypercholesterolemic subjects over an 8 wk period.
Methods
Subjects
A total of 65 volunteers aged between 18 and 80 years were
recruited in the region of Jena. Eligibility criterion was a
total cholesterol concentration of ≥ 5.2 mmol/L at screen-
ing, determined either by a general practitioner or on-site
using a hand-held point of care device from capillary blood
(Accutrend® Plus System, Roche Diagnostics, Grenzach-
Wyhlen, Germany). Exclusion criteria were treatment with
lipid-lowering drugs, intake of nutritional supplements,
which potentially influence lipid metabolism, and intoler-
ance, allergy or a strong dislike to any food ingredient
present in the protein drinks used in the study. In addition,
breast-feeding mothers or pregnant females were excluded.
Thus, 33 eligible participants (18 females, 15 males) were
invited to an in-person meeting. Here, participants were of-
fered essential study-relevant information and also pro-
vided with a study folder containing print information.
Written informed consent was obtained from all subjects
before start of the study. The study protocol was approved
by the Ethics Committee of the Medical Faculty of the
Friedrich Schiller University, Jena (no.: 2607-07/09).
Study design
The current study was part of a larger investigation
consisting of two intervention studies examining the influ-
ence of two different daily doses of LPI: 25 g (present
study) and 40 g [12] and comparing these with the effects
of the respective doses of MPI. The present study used a
randomized, double-blind crossover design consisting of
two 8 wk intervention periods separated by a 4 wk wash-
out period. The study was conducted between March and
August 2011 at the Department of Nutritional Physiology,
Friedrich Schiller University of Jena. Before commence-
ment subjects were randomly assigned to one of two
randomization groups using computer-generated random
numbers. One group received LPI to start with (group
AB) and the other group MPI first (group BA, Figure 1).
Research assistants involved in the randomization proced-
ure did not have access to any information regarding
demographic or laboratory characteristics of the subjects.
Moreover, protein drinks were labeled with numeric codes
and all research assistants as well as the participants were
blinded to group assignments.
Study products
The daily portion of 25 g LPI or MPI was dissolved in
500 mL water. The protein drinks produced by Nutrichem
Excluded (n = 32)
- Not meeting inclusion 
criteria (n = 21)
- Declined to participate (n = 7)
- Loss of contact (n = 4)
Analyzed
(n = 16)
- Excluded from analysis (n = 0)
Allocated to randomization group 
AB (n = 16)
Allocated to randomization group 
BA (n = 17)
Randomized
(n = 33)












- Excluded from analysis (n = 0)
Figure 1 Flow chart of participants at each stage of the intervention study. LPI, lupin protein isolate; MPI, milk protein isolate.
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a 4 wk supply in 250 mL sealed packages. Thus, 100 mL
of the protein drink contained either 5.0 g LPI or the iso-
nitrogenous amount of 5.1 g MPI. The amino acid compo-
sitions of the protein drinks are shown in Table 1. Fat
(3.0 g/100 mL) and carbohydrates (3.5 g/100 mL) were
added to obtain a pleasant taste and texture and to mask
potential differences between the protein drinks. Subjects
were instructed to maintain their usual level of physical
activity as well as their dietary habits throughout the
whole study. However, subjects were advised to replace an
iso-caloric part of their usual diet with the protein drinks
since these provided an additional energy intake of
1190 kJ/d.
The LPI was provided by the Fraunhofer Institute for
Process Engineering and Packaging (Fh-IVV, Freising,
Germany) in the form of the protein isolate type E. It
was produced from the seeds of Lupinus angustifolius
cv. Boregine as described by D'Agostina et al. [13]. This
LPI contained 81.6 ± 1.3% protein (nitrogen × 5.8) and
low quantities of water (5.7 ± 0.0%), ash (4.4 ± 0.0%),
fiber (6.0 ± 0.4%), and fat (1.4 ± 0.1%) in fresh matter. In
general, LPI type E contains the conglutins α, β, and δ[14] and is almost free of conglutin γ. Furthermore, it
has low quantities of alkaloids represented only by
lupanine (34.1 ± 3.1 mg/kg) [15].
In order to compare LPI with a high quality protein of
similar palatability, a MPI consisting of a mixture of
75%:25% (wt%:wt%) sodium caseinate (EM7, DMV Inter-
national, Veghel, The Netherlands) and whey protein
Megglosat HP (ME, Meggle, Wasserburg, Germany) was
chosen as active comparator. Sodium caseinate was
made up of 88.9 ± 1.0% protein (nitrogen × 6.38), water
(5.9 ± 0.0%), ash (4.4 ± 0.0%), fiber (2.8 ± 0.1%), and fat
(0.6 ± 0.0%) in fresh matter. Megglosat HP consisted of
84.8 ± 2.6% protein (nitrogen × 6.38), water (6.6 ± 0.1%),
ash (4.9 ± 0.0%), fiber (3.6 ± 0.0%), and fat (1.3 ± 0.2%) in
fresh matter. The nutrient composition of the protein
isolates was analyzed by applying standard methods with
reference to the “Association of Analytical Communi-
ties” [16] and the European Community Directive [17].
Data collection
At baseline participants recorded their usual daily eating
patterns in a 5 d food record with a precise documenta-
tion of weights and types of all consumed foods and
Table 1 Relative amino acid composition of the two
protein drinks administered in the study
Amino acid (%) LPI drink MPI drink
n = 3 n = 3
Alanine 3.2 ± 0.2 3.0 ± 0.1
Arginine 10.9 ± 0.5 3.3 ± 0.1
Aspartate + asparagine 10.4 ± 0.5 7.1 ± 0.2
Cystine 1.4 ± 0.3 0.8 ± 0.1
Glutamate + glutamine 23.2 ± 1.1 21.2 ± 0.3
Glycine 4.0 ± 0.2 1.8 ± 0.1
Histidine 2.4 ± 0.1 2.5 ± 0.1
Isoleucine 3.8 ± 0.3 4.4 ± 0.1
Leucine 7.3 ± 0.3 9.2 ± 0.2
Lysine 4.2 ± 0.2 8.0 ± 0.1
Methionine 0.4 ± 0.1 2.5 ± 0.2
Phenylalanine 3.9 ± 0.2 4.6 ± 0.2
Proline 8.8 ± 3.8 9.4 ± 1.4
Serine 5.0 ± 0.3 5.5 ± 0.1
Threonine 3.2 ± 0.3 4.8 ± 0.5
Tryptophan 1.2 ± 1.2 1.5 ± 0.6
Tyrosine 3.6 ± 0.4 5.0 ± 0.2
Valine 3.3 ± 0.2 5.6 ± 0.1
Values are presented as mean ± standard deviation.
Abbreviation: LPI lupin protein isolate, MPI milk protein isolate.
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mated with the use of PRODI® 5.9 (Nutri-Science GmbH,
Freiburg, Germany). At the end of each intervention
period, subjects consumed a standard diet including the
protein drinks. This standard diet was prepared and
preweighed in the study center and contained all foods re-
quired per subject over 2 d. Subjects were instructed to
consume no other foods, except for water. Food intake
was calculated by weighing food residues.
Body weight, body composition as well as blood pressure
were determined at baseline and after 8 wk of each inter-
vention period. Fasting participants were weighed with
light clothes and without shoes using a digital scale. Body
composition was determined using bioelectrical impedance
analysis (BIA 2000-S, Data Input GmbH, Darmstadt,
Germany). Blood pressure was measured in a sitting pos-
ition in duplicate after 10 min of rest on the left arm using
an automatic blood pressure monitor (boso-medicus uno,
Bosch + Sohn GmbH u. Co. KG, Jungingen, Germany).
Blood samples were collected at baseline, and after 4 wk
and 8 wk of each intervention period. Following 12 h over-
night fasting, blood samples were drawn by venipuncture
into a serum gel tube and a plasma gel tube containing lith-
ium heparin (Sarstedt AG & Co., Nümbrecht, Germany).
Serum tubes were centrifuged at 20°C, 2500 × g for 10 min,
the serum supernatants were aliquoted and stored at –80°Cuntil analysis. Plasma gel tubes were centrifuged at 15°C,
4302 × g for 7 min.Analytical methods
Fresh plasma was analyzed for total, LDL, and HDL chol-
esterol as well as for triacylglyceroles, urea, and hs-CRP
according to the protocols of the Institute of Clinical
Chemistry and Laboratory Medicine, Jena University Hos-
pital and quantified using the autoanalyzer ARCHITECT
C16000 (Abbott, Illinois, USA). For the analysis of free
amino acids in serum, the method based on the European
Community Directive [17] was applied as described previ-
ously [18].
Statistical analyses
Statistical analyses were conducted using PASS 6.0 (NCSS
Statistical Software, Kaysville, UT, USA) or SPSS 19.0
(SPSS Inc., Chicago, USA). In all analyses, differences were
considered as statistically significant with P ≤ 0.050. A
power analysis revealed > 80% power for the present study
to detect a 10% difference in the primary outcome measure
LDL cholesterol. All collected data were tested for normal
distribution and for homogeneity of variances applying the
Kolmogorov-Smirnov test and the Levene’s test, respect-
ively. Baseline characteristics and data of the nutrient in-
take were tested with the independent samples t-tests. A
repeated measures ANOVA with the general linear model
was used to identify differences between the two treat-
ments as well as changes over time. For data that were not
normally distributed and/or had heterogeneous variances,
a linear mixed model analysis was applied.
Results
Baseline characteristics and palatability of study products
All 33 individuals randomized in groups AB and BA com-
pleted both 8 wk intervention periods and were included
in final analyses (Figure 1). The baseline characteristics of
the subjects are shown in Table 2. The consumption of
the protein drinks was well accepted by most of the partic-
ipants and palatability ratings (evaluation scale from best
to worst, 1.0 to 6.0) differed slightly between MPI (2.2)
and LPI drinks (2.7).
Nutrient intake
The analysis of the 5 d food record provided information
regarding the composition of the diet at baseline. Energy
and carbohydrate intakes were in accordance with refer-
ence values, whereas protein, fat, and cholesterol intakes
were higher compared to recommended values [19]
(Table 3). Nutrient intake following consumption of the 2
d standard diet at wk 8 did not differ between the two
treatments LPI and MPI. In comparison to the diet at
baseline, the intake of energy, protein, and fat was
Table 2 Baseline characteristics of the 33
hypercholesterolemic subjects participating in both 8 wk
intervention periods
Randomization groups Group AB Group BA Pa
n 16 17 –
Age (y) 49.7 ± 12.8 49.4 ± 13.9 0.91
Females (n) 6 12 –
Current smoking (%) 33.0 16.7 –
Physical activity≥ 2 h/wk (%) 66.7 66.7 –
Anthropometric data
Body height (m) 1.7 ± 0.1 1.7 ± 0.1 0.44
Body weight (kg) 84.2 ± 25.3 76.4 ± 14.4 0.30
BMI (kg/m2) 28.8 ± 6.5 27.3 ± 5.4 0.48
Body fat (kg) 24.3 ± 12.1 24.9 ± 9.0 0.86
Blood pressure
Systolic BP (mm Hg) 143.9 ± 15.8 142.4 ± 17.3 0.81
Diastolic BP (mm Hg) 87.9 ± 12.0 85.7 ± 9.6 0.56
Pulse at rest (min-1) 69.6 ± 15.3 71.0 ± 13.6 0.78
Plasma parameters
Total cholesterol (mmol/L) 6.14 ± 1.00 6.88 ± 1.16 0.06
LDL cholesterol (mmol/L) 4.02 ± 1.09 4.69 ± 1.13 0.10
HDL cholesterol (mmol/L) 1.33 ± 0.37 1.58 ± 0.49 0.11
Triacylglyceroles (mmol/L) 2.03 ± 1.50 1.55 ± 0.79 0.28
LDL:HDL cholesterol ratio 3.33 ± 1.43 3.30 ± 1.40 0.95
Urea (mmol/L) 5.45 ± 1.37 4.58 ± 1.13 0.05
hs-CRPb (mg/L) 1.83 ± 2.30 2.02 ± 2.07 0.84
Values are presented as mean ± standard deviation, number or percentage.
Abbreviation: Group AB subjects receiving LPI in the first intervention period;
Group BA subjects receiving LPI in the second intervention period; LPI lupin
protein isolate, BP blood pressure, hs-CRP high-sensitivity C-reactive protein.
aP-value is for differences between randomization groups using independent
samples t-test.
bhs-CRP values of some participants had to be excluded due to a temporary
inflammatory status at time of measurement; group AB; n = 10; group
BA, n = 13.
Table 3 Nutrient intake calculated from the 5 d food record a
intervention with LPI and MPI
Food record
Nutrient D-A-CHb Baseline
Energy (MJ/d) (m) 10.5 (f) 8.5 9.8 ± 2.6
Protein (g/d) (m) 58.0 (f) 46.0 84.4 ± 25.9
Fat (g/d) (m) 77.0 (f) 60.0 94.3 ± 34.5
Carbohydrates (g/d) (m) 288 (f) 225 259 ± 78
Cholesterol (mg/d) (m) < 300 (f) < 300 374 ± 170
Values are presented as mean ± standard deviation, n = 33.
Abbreviation: LPI lupin protein isolate, MPI milk protein isolate, m males, f females.
aP-value is for differences between treatments at wk 8 determined by independent
bReference values from D-A-CH (2004) for males and females between 51 and 65 ye
*, **, ***Significant differences comparing wk 8 with baseline determined by indepen
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tein interventions (P ≤ 0.028).
Anthropometric data and blood pressure
No treatment effects in anthropometric data or blood
pressure were seen at wk 8 among the two protein inter-
ventions (Table 4). Compared to baseline, there was a
slight increase in body weight and body fat after 8 wk of
intervention with both LPI and MPI (P ≤ 0.045). Systolic
blood pressure was significantly reduced after 8 wk of
the two protein interventions (P ≤ 0.014). Diastolic blood
pressure and pulse at rest were decreased after 8 wk of
LPI intervention (P ≤ 0.044), whereas they remained con-
stant throughout the MPI intervention.
Plasma parameters
Plasma lipid parameters did not differ between the two
treatments, neither at wk 4 nor wk 8, except for a higher
HDL cholesterol concentration at wk 4 following inter-
vention with LPI (P = 0.036, Table 5). Compared to base-
line, after 4 wk but not after 8 wk, there was a decrease
in LDL cholesterol following both protein interventions
(P ≤ 0.008) and in LDL:HDL cholesterol ratio following
LPI intervention (P = 0.003). Concentrations of total
cholesterol and triacylglyceroles were not significantly
affected by the protein interventions, except for an in-
crease in triacylglyceroles after 8 wk of LPI intervention
(P = 0.022).
Considering the total cholesterol concentrations at
baseline, subjects with a higher initial total cholesterol
(> 6.6 mmol/L, n = 14) at an average of 7.6 mmol/L
showed a significant decrease in total and LDL choles-
terol after 4 wk of both interventions compared to base-
line (LPI: –0.34 ± 0.59 mmol/L and –0.62 ± 0.52 mmol/
L; MPI: –0.47 ± 0.76 mmol/L and –0.64 ± 0.55 mmol/L;
P ≤ 0.048; Figure 2). After 8 wk, a reduction of LDLt baseline and from the 2 d standard diet after 8 wk of
LPI MPI
Standard diet Standard diet
Changes from baseline Changes from baseline Pa
wk 8 wk 8 wk 8
1.21 ± 2.18* 1.3 ± 2.1* 0.78
22.8 ± 20.6*** 24.6 ± 20.7*** 0.69
18.5 ± 29.6** 19.7 ± 28.6** 0.80
16 ± 68 18 ± 71 0.83
−57 ± 140 −49 ± 137 0.69
samples t-test.
ars.
dent samples t-test (* P ≤ 0.050, ** P ≤ 0.010, *** P ≤ 0.001).
Table 4 Anthropometric data at baseline and changes after 8 wk of intervention with LPI and MPI
LPI MPI
Changes from baseline Changes from baseline Pa
Baseline wk 8 wk 8 wk 8
Body weight (kg) 80.0 ± 20.2 0.6 ± 1.6* 0.7 ± 1.5** 0.61
BMI (kg/m2) 28.0 ± 5.9 0.2 ± 0.6* 0.2 ± 0.5** 0.67
Body fat (kg) 24.6 ± 10.3 0.5 ± 1.3* 0.6 ± 1.2** 0.65
Systolic BP (mm Hg) 143.1 ± 16.4 −8.4 ± 13.6*** −5.9 ± 12.9* 0.29
Diastolic BP (mm Hg) 86.7 ± 10.7 −2.7 ± 7.5* −1.5 ± 7.7 0.31
Pulse at restb (min-1) 70.4 ± 14.2 −4.0 ± 10.8* −1.8 ± 7.6 0.16
Values are presented as mean ± standard deviation, n = 33.
Abbreviation: LPI lupin protein isolate, MPI milk protein isolate, BP blood pressure.
aP-value is for differences between treatments at wk 8 determined by repeated measures ANOVA.
bData were not normally distributed and/or had heterogeneous variances, and thus were statistically analyzed using a linear mixed model.
*, **, *** Significant differences comparing wk 8 with baseline determined by repeated measures ANOVA (* P ≤ 0.050, ** P ≤ 0.010, *** P ≤ 0.001).
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lowing LPI intervention (–0.35 ± 0.54 mmol/L; P = 0.032).
LDL:HDL cholesterol ratios were significantly decreased
after 4 wk of LPI and MPI intervention (LPI: –0.68 ±
0.52 mmol/L; MPI: –0.52 ± 0.64 mmol/L; P ≤ 0.009; data
not shown). In contrast, in subjects with moderately ele-
vated initial total cholesterol (≤ 6.6 mmol/L, n = 19) at an
average of 5.8 mmol/L, no changes in total and LDL chol-
esterol (Figure 2) as well as in LDL:HDL cholesterol ratio
(data not shown) could be observed, both after 4 wk and
after either 8 wk of LPI or MPI intervention.
There were no significant differences between the two
treatments with respect to hs-CRP and urea in plasma at
wk 4 or wk 8 (Table 5). Concentrations of hs-CRP de-
creased after 4 wk and 8 wk of LPI as well as MPI inter-
vention compared to baseline. However, these differences
did not reach statistical significance (P ≤ 0.82). Compared
to baseline, the concentrations of plasma urea were in-
creased after 4 wk of both protein interventions (P ≤Table 5 Plasma concentrations of blood lipids, hs-CRP, and u
intervention with LPI and MPI
LPI
Changes from base
Baseline wk 4 w
Total cholesterol (mmol/L) 6.54 ± 1.14 −0.12 ± 0.48 −0.05
LDL cholesterol (mmol/L) 4.38 ± 1.14 −0.26 ± 0.53** −0.08
HDL cholesterol (mmol/L) 1.46 ± 0.45 0.04 ± 0.15 −0.05
Triacylglyceroles (mmol/L) 1.77 ± 1.17 0.08 ± 0.59 0.19
LDL:HDL cholesterol ratio 3.32 ± 1.39 −0.29 ± 0.53** 0.02
hs-CRPb, c (mg/L) 1.93 ± 2.12 −0.23 ± 1.29 −0.28
Urea (mmol/L) 4.98 ± 1.30 0.59 ± 0.94*** 0.47
Values are presented as means ± standard deviation, n = 33.
Abbreviation: LPI lupin protein isolate, MPI milk protein isolate, hs-CRP high-sensitiv
aP-value is for differences between treatments at wk 4 or at wk 8 determined by re
bData were not normally distributed and/or had heterogeneous variances, and thus
c n = 23, hs-CRP values of some participants had to be excluded due to a temporary
*, **, ***Significant differences comparing wk 4 and wk 8 with baseline determined b0.001). Following 8 wk of both protein interventions,
plasma urea was still higher compared to baseline (P ≤
0.022), however, the magnitude was smaller than after 4
wk of intervention.Serum amino acids
Serum amino acid concentrations at baseline, treatment
effects, and changes over time are shown in Table 6. Ex-
cept for aspartate, glycine and arginine, the concentra-
tions of proteinogenic amino acids were significantly
higher at wk 4 (P ≤ 0.042) for MPI relative to LPI. How-
ever, there were no significant differences between the
two treatments at wk 8. Compared to baseline, the con-
centrations of almost all single amino acids increased
after 4 wk, but not after 8 wk of intervention with MPI
(P ≤ 0.019). Following the 4 wk and 8 wk intervention
with LPI, most of the amino acid concentrations
remained unchanged.rea at baseline and changes after 4 wk and 8 wk of
MPI
line Changes from baseline Pa Pa
k 8 wk 4 wk 8 wk 4 wk 8
± 0.44 −0.22 ± 0.63 0.02 ± 0.49 0.36 0.52
± 0.50 −0.32 ± 0.54** −0.06 ± 0.34 0.47 0.90
± 0.19 −0.03 ± 0.18 −0.02 ± 0.13 0.036 0.20
± 0.45* 0.17 ± 0.70 0.16 ± 0.77 0.59 0.77
± 0.53 −0.20 ± 0.62 −0.05 ± 0.39 0.34 0.29
± 1.38 −0.09 ± 1.17 −0.32 ± 1.41 0.63 0.89
± 1.10* 0.78 ± 1.19*** 0.44 ± 1.06* 0.36 0.86
ity C-reactive protein.
peated measures ANOVA.
were statistically analyzed using a linear mixed model.
inflammatory status at time of measurement.














LPI wk 4 
LPI wk 8 
MPI wk 4 


















Pa = 0.045 
Figure 2 Plasma cholesterol concentrations [mmol/L] at baseline and after 4 wk and 8 wk of intervention with LPI and MPI in subjects
with moderate or higher hypercholesterolemia. The study population was differentiated into two subgroups based on the total cholesterol
concentration at baseline. Subjects with a cholesterol concentration≤ 6.6 mmol/L were considered to have moderate hypercholesterolemia (n = 19);
subjects with a cholesterol concentration > 6.6 mmol/L were considered to have higher hypercholesterolemia (n = 14). LPI, lupin protein isolate; MPI,
milk protein isolate. a P-value is for difference between treatments at wk 8 determined by repeated measures ANOVA. *, *** Significant differences
comparing wk 4 and wk 8 with baseline determined by repeated measures ANOVA (* P≤ 0.050, *** P≤ 0.001).
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This randomized crossover study reveals that a modest
amount comprising 25.0 g/d of additionally consumed LPI
is capable of lowering total (−5%) and LDL cholesterol
concentrations (–12%) as well as the LDL:HDL cholesterol
ratio (−16%) from baseline to wk 4, primarily in subjects
with higher hypercholesterolemia (> 6.6 mmol/L).
The lipid-lowering activity of dietary treatments appears
to be strongly dependent on the subjects’ initial choles-
terol concentrations [20,21]. A meta-analysis of 38 human
studies on soy protein ascertained that the net changes in
total as well as in LDL cholesterol after intervention were
directly related to the total cholesterol concentration at
baseline [20]. A more recent re-evaluation by Sirtori et al.
[21] which included a further 33 studies on soy protein
confirmed this dependency. In line with this, a subgroup
analysis within the present study revealed that the total
and LDL cholesterol-lowering activities of LPI and MPI
were restricted to subjects with higher initial total choles-
terol with an average of 7.6 mmol/L (Figure 2) indicating
that there is a similar dependency between cholesterol-
lowering activity and baseline cholesterol concentrations
for lupin protein.
As reviewed by Anderson and Konz [22], a 1% increase
in either total or LDL cholesterol increases the risk for cor-
onary heart disease by 2% to 3% and 1%, respectively. Thus,
after a 4 wk LPI intervention the risk for cardiovascular
events such as coronary heart diseases would be reduced
by 10% to 15% in subjects with higher hypercholesterol-
emia. Due to the lack of change in subjects with moderate
hypercholesterolemia, the lipid-lowering effects for the
whole study population were lower. The overall changes in
plasma cholesterol after 4 wk of intervention are consistent
with two other studies that show a LDL cholesterol- [8]and a moderate total cholesterol-lowering activity [8,9] of
35.0 g/d lupin protein consumed by hypercholesterolemic sub-
jects over a short-term period of 4 wk or 6 wk. A recent study
conducted by our workgroup in hypercholesterolemic subjects
revealed a decrease in the LDL:HDL cholesterol ratio by 7%
after consumption of 40.0 g/d LPI over 8 wk, whereas total
and LDL cholesterol were not altered [12]. In contrast, Belski
et al. [23] and Hodgson et al. [24] did not find changes in
plasma lipid concentrations in overweight or obese partic-
ipants following a long-term intervention from 16 wk to
twelve months with an ad libitum diet higher in protein
and fiber obtained by enriching foods with lupin flour.
The present study showed a significant reduction in
systolic blood pressure by 8.4 mm Hg after 8 wk of LPI
intervention. Since an increase of 1 mm Hg in systolic
blood pressure is expected to increase the risk for coron-
ary heart disease by 2.4% [22] the observed effect in our
study could reduce the risk by 20%. These results are
consistent with three previous studies that found a sig-
nificant decline in blood pressure following consumption
of lupin protein [7] or lupin flour [23,25].
Similar to the findings of Weisse et al. [8], LPI interven-
tion per se only minimally changed amino acid profile
(Table 6). The concentrations of methionine were de-
creased by 8% after 4 wk equivalent to the observed 7%
decline in the study by Weisse et al. [8]. Since LPI relative
to MPI had almost a threefold higher arginine and half the
lysine proportion (Table 1), at wk 4, but not at wk 8 of LPI
intervention, the lysine:arginine ratio in serum was signifi-
cantly lower compared to MPI (Table 6).
Evidently, there was a general decrease in the extent of
physiological effects of both protein interventions from wk 4
to wk 8. This aspect may be explained by a declining compli-
ance to the study protocol after 4 wk of intervention, which
Table 6 Serum concentrations of amino acids at baseline and changes after 4 wk and 8 wk of intervention with LPI
and MPI
LPI MPI
Changes from baseline Changes from baseline Pa Pa
Amino acid (μmol/L) Baseline wk 4 wk 8 wk 4 wk 8 wk 4 wk 8
Alanine 425.0 ± 147.6 −1.1 ± 98.2 1.8 ± 132.2 45.1 ± 102.0* 2.6 ± 121.8 0.022 0.96
Arginine 96.2 ± 30.3 1.0 ± 24.7 9.0 ± 28.4 4.6 ± 28.3 3.1 ± 29.8 0.43 0.18
Asparagine 48.9 ± 13.9 2.8 ± 16.0 7.2 ± 16.3* 7.8 ± 12.5*** 3.1 ± 12.1 0.08 0.09
Aspartateb 19.6 ± 8.9 −4.0 ± 10.5* −6.2 ± 7.5*** −1.1 ± 8.5 −6.8 ± 8.9*** 0.22 0.56
Cystine 65.2 ± 18.5 −3.3 ± 12.5 1.9 ± 16.0 2.2 ± 12.4 1.4 ± 15.9 0.025 0.81
Glutamine 623.7 ± 169.6 −22.7 ± 105.8 14.2 ± 132.0 30.6 ± 132.1 19.0 ± 150.4 0.026 0.84
Glutamateb 55.5 ± 27.8 −9.3 ± 25.2* −14.6 ± 20.3** 3.3 ± 28.9 −15.1 ± 22.0** 0.038 0.89
Glycine 246.1 ± 82.4 −14.5 ± 50.5 −10.6 ± 63.8 0.8 ± 58.1 −13.4 ± 66.8 0.17 0.76
Histidine 90.5 ± 26.1 −4.9 ± 19.0 6.9 ± 21.5 8.2 ± 21.6 3.5 ± 23.3 0.001 0.24
Isoleucine 63.5 ± 32.0 3.2 ± 28.2 4.2 ± 27.6 13.4 ± 31.3* 2.9 ± 28.3 0.014 0.70
Leucine 145.2 ± 48.4 0.9 ± 40.9 7.0 ± 39.6 24.5 ± 48.1** 6.4 ± 41.8 0.002 0.91
Lysine 200.2 ± 57.2 −8.4 ± 50.7 9.8 ± 53.3 29.7 ± 58.0** 18.0 ± 58.4 0.0001 0.29
Methionine 22.9 ± 7.8 −1.9 ± 7.1 0.4 ± 7.4 3.8 ± 8.3* 0.5 ± 7.8 < 0.0001 0.96
Phenylalanine 66.8 ± 16.4 −1.4 ± 15.8 1.7 ± 18.5 8.4 ± 18.0* 1.6 ± 18.4 0.003 0.98
Prolineb 169.7 ± 99.9 18.8 ± 112.9 24.5 ± 101.0 81.8 ± 184.1** 39.7 ± 117.2 0.007 0.31
Serineb 112.4 ± 35.6 −9.8 ± 29.2 −3.8 ± 30.8 5.1 ± 28.9 −4.6 ± 27.0 0.042 0.87
Threonineb 132.5 ± 49.7 −6.0 ± 35.8 2.2 ± 39.7 14.6 ± 37.1 7.7 ± 40.8 0.013 0.38
Tryptophan 76.0 ± 27.7 −7.3 ± 25.2 9.4 ± 44.9 4.8 ± 28.6 −1.3 ± 28.2 0.010 0.13
Tyrosine 75.2 ± 22.8 −0.5 ± 18.8 4.2 ± 21.3 16.0 ± 27.7** 4.3 ± 19.0 0.002 0.98
Valine 243.5 ± 87.3 −3.8 ± 75.8 13.4 ± 64.5 45.6 ± 78.1** 24.6 ± 79.2 0.0004 0.29
EAA 1041.1 ± 313.0 −29.5 ± 261.3 54.9 ± 254.4 153.2 ± 302.9** 63.8 ± 297.5 0.0003 0.79
Non-EAA 1937.4 ± 507.4 −42.3 ± 382.2 27.7 ± 458.8 196.2 ± 478.1* 33.2 ± 458.2 0.005 0.93
BCAA 452.2 ± 165.4 0.3 ± 142.1 24.6 ± 126.8 83.6 ± 154.7** 33.9 ± 145.3 0.001 0.62
Lysine:arginine ratio 2.16 ± 0.55 −0.14 ± 0.32* −0.04 ± 0.28 0.17 ± 0.35** 0.10 ± 0.34 0.0004 0.16
Values are presented as means ± standard deviation, n = 33.
Abbreviation: LPI lupin protein isolate, MPI milk protein isolate, EAA essential amino acids, Non-EAA non-essential essential amino acids, BCAA branched chained
amino acids.
a P-value is for differences between treatments at wk 4 or at wk 8 determined by repeated measures ANOVA.
b Data were not normally distributed and/or had heterogeneous variances, and thus were statistically analyzed using a linear mixed model.
*, **, *** Significant differences comparing wk 4 and wk 8 with baseline determined by repeated measures ANOVA (* P ≤ 0.050, ** P ≤ 0.010, *** P ≤ 0.001).
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(Table 5). As there was an increase in energy intake (Table 3)
as well as in body weight and body fat (Table 4) after 8 wk of
both protein interventions compared to baseline, we can
presume that the majority of subjects did not replace an iso-
caloric part of their usual diet with the protein drinks. A de-
crease in body weight is associated with lower concentrations
of triacylglyceroles, total and LDL cholesterol as well as with
higher HDL cholesterol [26]. Thus, the observed weight gain
might have additionally contributed to a worsening of the
lipid profile from wk 4 to wk 8.
There were no significant differences in the plasma
concentrations of cholesterol and of hs-CRP or in blood
pressure between LPI and MPI intervention. This lack of
treatment effects is not entirely surprising since severalstudies attribute milk proteins, particularly several milk
peptides, with beneficial physiological properties such as
hypocholesterolemic, hypotensive, and anti-inflammatory
activities [3]. Furthermore, increasing evidence indicates
that the substitution of protein from animal as well as plant
sources at the expense of carbohydrates may beneficially
affect plasma lipids [4], facilitates loss of body weight [27]
and body fat [28], and can lower blood pressure [5]. The
mechanisms and bioactive components of lupin protein re-
sponsible for the beneficial effects in the human body have
not yet been elucidated [6]. Contrary to soy, proteins from
lupin are almost free from isoflavones [29] and thus
physiological effects can be attributed to the protein and/
or its components per se. According to Rahman et al. [30],
the low lysine:arginine ratio might be responsible for the
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reported by Rajamohan and Kurup [31], a decrease in
serum cholesterol in rats was caused by a globulin fraction
of sesame seeds with a low lysine:arginine ratio of 0.67
comparable to the value determined for the LPI (0.38) used
in the present study. However, studies on the impact of dif-
ferent lysine:arginine ratios on lipid metabolism are lack-
ing. Notably, the high proportion of arginine amounting to
around 10% in lupin protein should be taken into consider-
ation with regard to the physiological impact. Recent stud-
ies indicate that arginine is capable of modulating the
concentrations of lipid signaling molecules [32,33] and the
expression of genes involved in the regulation of lipid
homeostasis [32] which might lead to changes in the con-
centration of cholesterol. Hurson et al. [34] investigated
the effect of an oral supplementation with 17 g arginine
over 2 wk in elderly subjects. In the arginine-supplemented
group, total cholesterol significantly decreased by 10% due
mainly to reduced LDL cholesterol (-10%), whilst HDL
cholesterol remained constant. These observed changes in
cholesterol concentrations are in accordance with the re-
sults of the present study after 4 wk of 25 g/d LPI interven-
tion. However, in the current study, the arginine uptake of
2.5 g/d via LPI was much lower than the supplemented
17 g/d arginine in the study by Hurson et al. [34]. Lupin
protein seems to affect the expression of hepatic genes in-
volved in lipid metabolism as previously shown in hyper-
cholesterolemic rats [35,36] and, further, to alter the
activity of LDL receptor as shown in a human hepatoma
cell line [29]. Supporting these results, Weisse et al. [8] ob-
served an increase in mRNA abundance of the sterol regu-
latory element-binding protein-2 and LDL receptor along
with a decrease in mRNA concentrations of 3-hydroxy-3-
methylglutaryl-CoA reductase in mononuclear blood cells
from hypercholesterolemic subjects after 6 wk intervention
with 35 g/d lupin protein. Apart from the specific amino
acid profile of lupin protein, several bioactive peptides as
well as entire proteins are equally capable of demonstrating
favorable properties [6].
In the present study, we could not detect a
triacylglycerole-lowering activity of LPI. Thus, the in-
consistent experimental data referring to the effect of
lupin protein on triacylglyceroles [7-9] indicates the ne-
cessity of an inclusion of this parameter in further hu-
man studies. Furthermore, in future studies, it may be
desirable to incorporate the test proteins in usual diet-
ary foods in order to increase the subjects’ compliance
and to avoid changes in dietary composition, thereby
sustain body weight and body composition over the
whole study time.
Conclusion
The present study suggests that the supplementation of
25 g/d LPI positively affects LDL cholesterol and LDL:HDL cholesterol ratio particularly in subjects with higher
hypercholesterolemia. These beneficial effects, were how-
ever, largely absent after 8 wk of intervention, due most
likely to a declining compliance from wk 4 to wk 8.
Based on our results, we do not expect any adverse ef-
fects of lupin protein when integrated in human nutri-
tion above all because the protein is almost free from
isoflavones. Lupin therefore can be considered as an al-
ternative and valuable source of plant protein with re-
spect to soy protein. Moreover, supplementation of
modest amounts of lupin protein into the diet could
provide a safe and non-pharmacological approach of at-
tenuating the extent of hypercholesterolemia, thereby
reducing the risk of cardiovascular diseases.
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